May. 4 at 2:32 PM
$ABCL is starting to get momentum again — +5% on the day and pressing higher.
The key narrative now is ABCL635 Phase 2 data shifting sentiment. This is where biotech moves are made — not on hype, but on data read-through expectations
They’ve also got ~
$700M cash on the balance sheet, which gives them real runway. In biotech terms, that’s time + optionality while others are forced to dilute or stall.
Technically, bulls are pointing toward a Wave 3 extension into ~
$5.08, with longer-term chatter around
$10 if the data cycle continues to improve.
Follow me 👉@ChipDistribution7 for real-time updates and everything. Let’s make moves!
